GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regeneron Pharmaceuticals Inc (NAS:REGN) » Definitions » Pretax Margin %

Regeneron Pharmaceuticals (Regeneron Pharmaceuticals) Pretax Margin % : 33.42% (As of Dec. 2023)


View and export this data going back to 1991. Start your Free Trial

What is Regeneron Pharmaceuticals Pretax Margin %?

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Regeneron Pharmaceuticals's Pre-Tax Income for the three months ended in Dec. 2023 was $1,148 Mil. Regeneron Pharmaceuticals's Revenue for the three months ended in Dec. 2023 was $3,434 Mil. Therefore, Regeneron Pharmaceuticals's pretax margin for the quarter that ended in Dec. 2023 was 33.42%.

The historical rank and industry rank for Regeneron Pharmaceuticals's Pretax Margin % or its related term are showing as below:

REGN' s Pretax Margin % Range Over the Past 10 Years
Min: 27   Med: 36.22   Max: 58.03
Current: 32.01


REGN's Pretax Margin % is ranked better than
92.99% of 1027 companies
in the Biotechnology industry
Industry Median: -176.72 vs REGN: 32.01

Regeneron Pharmaceuticals Pretax Margin % Historical Data

The historical data trend for Regeneron Pharmaceuticals's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regeneron Pharmaceuticals Pretax Margin % Chart

Regeneron Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Pretax Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 37.04 44.84 58.03 39.91 32.01

Regeneron Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 38.80 27.13 34.29 33.03 33.42

Competitive Comparison of Regeneron Pharmaceuticals's Pretax Margin %

For the Biotechnology subindustry, Regeneron Pharmaceuticals's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regeneron Pharmaceuticals's Pretax Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regeneron Pharmaceuticals's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Regeneron Pharmaceuticals's Pretax Margin % falls into.



Regeneron Pharmaceuticals Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Regeneron Pharmaceuticals's Pretax Margin for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Margin=Pre-Tax Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=4199.3/13117.2
=32.01 %

Regeneron Pharmaceuticals's Pretax Margin for the quarter that ended in Dec. 2023 is calculated as

Pretax Margin=Pre-Tax Income (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=1147.6/3434.3
=33.42 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Regeneron Pharmaceuticals  (NAS:REGN) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.


Regeneron Pharmaceuticals Pretax Margin % Related Terms

Thank you for viewing the detailed overview of Regeneron Pharmaceuticals's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Regeneron Pharmaceuticals (Regeneron Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
777 Old Saw Mill River Road, Tarrytown, NY, USA, 10591-6707
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).
Executives
Bonnie L Bassler director REGENERON PHARMACEUTICALS, INC., 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Arthur F Ryan director CITIZENS FINANCIAL GROUP, INC, 600 WASHINGTON BOULEVARD, STAMFORD CT 06901
George Yancopoulos director, officer: President and CSO 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Huda Y Zoghbi director REGENERON PHARMACEUTICALS, INC., 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Marion Mccourt officer: SVP Commercial C/O AXOVANT SCIENCES, INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018
Michael S Brown director
Christopher R. Fenimore officer: VP, Controller REGENERON PHARMACEUTICALS, INC., 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Andrew J Murphy officer: EVP Research REGENERON PHARMACEUTICALS, INC., 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Kathryn Guarini director 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
David P Schenkein director C/O BLUEBIRD BIO, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Van Plew Daniel P officer: EVP & General Mgr Industrial O REGENERON PHARMACEUTICALS, INC., 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Robert E Landry officer: SVP Fin, Dep CFO 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Christine A Poon director C/O JOHNSON & JOHNSON, ONE JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Neil Stahl officer: SVP, Preclinical Development 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Joseph L Goldstein director DEPT OF PHARMACOLOGY K5 YUVER OF TEXAS, 5323 HARRY HINES BLVD, DALLAS TX 75390